NCT01197235

Effect of Darbepoetin in Contrast-induced Nephropathy

Prevention of Contrast-Induced Nephropathy by Darbepoetin in Patients With Chronic Kidney Disease

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney disease.

Detailed description

Use of radiocontrast agent is inevitable in computed tomography or angiography. However, contrast agent can aggravate kidney function. Contrast-induced nephropathy (CIN) refers to the clinical situation where decreased kidney function after use of contrast. CIN is the 3rd most common cause of acute kidney injury in the hospitals. There are a lot of reports that death rate is increased in patients with CIN. Erythropoietin is an agent that treat anemia. It also has been reported to have a tissue-protective effect in the animal experiments. In this study, we hypothesized that erythropoietin can reduce the incidence of CIN in patients with chronic kidney disease undergoing coronary angiography.

Conditions

• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	darbepoetin-α	Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
DRUG	isotonic saline	Infusion of isotonic saline will be performed 1 hour before angiography

Timeline

• Start date: 2009-05-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2010-09-09
• Last updated: 2014-11-21

Locations

1 site across 1 country: South Korea